Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS Pathog ; 5(5): e1000450, 2009 May.
Article in English | MEDLINE | ID: mdl-19478868

ABSTRACT

The interferon-induced transmembrane protein BST-2/CD317 (tetherin) restricts the release of diverse enveloped viruses from infected cells. The HIV-1 accessory protein Vpu antagonizes this restriction by an unknown mechanism that likely involves the down-regulation of BST-2 from the cell surface. Here, we show that the optimal removal of BST-2 from the plasma membrane by Vpu requires the cellular protein beta-TrCP, a substrate adaptor for a multi-subunit SCF E3 ubiquitin ligase complex and a known Vpu-interacting protein. beta-TrCP is also required for the optimal enhancement of virion-release by Vpu. Mutations in the DSGxxS beta-TrCP binding-motif of Vpu impair both the down-regulation of BST-2 and the enhancement of virion-release. Such mutations also confer dominant-negative activity, consistent with a model in which Vpu links BST-2 to beta-TrCP. Optimal down-regulation of BST-2 from the cell surface by Vpu also requires the endocytic clathrin adaptor AP-2, although the rate of endocytosis is not increased; these data suggest that Vpu induces post-endocytic membrane trafficking events whose net effect is the removal of BST-2 from the cell surface. In addition to its marked effect on cell-surface levels, Vpu modestly decreases the total cellular levels of BST-2. The decreases in cell-surface and intracellular BST-2 are inhibited by bafilomycin A1, an inhibitor of endosomal acidification; these data suggest that Vpu induces late endosomal targeting and partial degradation of BST-2 in lysosomes. The Vpu-mediated decrease in surface expression is associated with reduced co-localization of BST-2 and the virion protein Gag along the plasma membrane. Together, the data support a model in which Vpu co-opts the beta-TrCP/SCF E3 ubiquitin ligase complex to induce endosomal trafficking events that remove BST-2 from its site of action as a virion-tethering factor.


Subject(s)
HIV-1/pathogenicity , Human Immunodeficiency Virus Proteins/physiology , Lysosomes/metabolism , Membrane Glycoproteins/antagonists & inhibitors , Viral Regulatory and Accessory Proteins/physiology , beta-Transducin Repeat-Containing Proteins/metabolism , Adaptor Protein Complex 2 , Antigens, CD/genetics , Antigens, CD/metabolism , Cell Line , Down-Regulation , Endosomes/metabolism , GPI-Linked Proteins , HIV-1/physiology , Human Immunodeficiency Virus Proteins/genetics , Humans , Membrane Glycoproteins/genetics , Membrane Glycoproteins/metabolism , Mutation , Protein Transport , Viral Regulatory and Accessory Proteins/genetics , beta-Transducin Repeat-Containing Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...